Abstract
Objective
The present study was conducted to evaluate the efficacy and safety of a combination regimen of S-1, paclitaxel plus cisplatin in patients with advanced gastric cancer.
Methods
Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous paclitaxel 80 mg/m2 plus cisplatin 30 mg/m2 on days 1, 8 and S-1 35 mg/m2 orally twice daily on days 1–14 based on a 3-week cycle.
Results
Forty-four patients were enrolled in the current study, among whom 38 were assessable for efficacy and all assessable for toxicity. Two complete response and 24 partial responses were confirmed, giving an overall response rate of 59.1%. At a median follow-up of 11.4 months, the median time to progression and median overall survival was 9.4 (95% CI 6.8–12.1) months and 11.2 (95% CI 7.6–14.8) months, respectively. Grade 3/4 neutropenia occurred in 45 events (20.9%) and febrile neutropenia was observed in five events (2.3%). The common non-hematologic toxicity was nausea (grade 1/2, 27.2%) and diarrhea (grade 1/2, 9.0%).
Conclusion
The combination of S-1, paclitaxel and cisplatin was found to be well tolerated and effective in patients with advanced gastric cancer.
Similar content being viewed by others
References
Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481–488
Murad AM, Santiago FF, Petroianu A et al (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37–41
Pyrhonen S, Kuitunen T, Nyandoto P et al (1995) Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587–591
Glimelius B, Ekstrom K, Hoffman K et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163–168
Maehara Y (2003) S-1 in gastric cancer: a comprehensive review. Gastric Cancer 6(Suppl 1):2–8
Sakata Y, Ohtsu A, Horikoshi N et al (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur–0.4 M gimestat–1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715–1720
Koizumi W, Kurihara M, Nakano S et al (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58:191–197
Chollet P, Schoffski P, Weigang-Kohler K et al (2003) Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 39:1264–1270
Ohtsu A, Boku N, Tamura F et al (1998) An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 21:416–419
Yamada Y, Shirao K, Ohtsu A et al (2001) Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 12:1133–1137
Emi Y, Yamamoto M, Takahashi I et al (2008) Phase II study of weekly palcitaxel by one-hour infusion for advanced gastric cancer. Surg Today 38:1013–1020
Kim JG, Sohn SK, Song HS et al (2007) Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 60:863–869
Ajani JA, Fairweather J, Dumas P et al (1998) Phase II study of taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 4:269–274
Bokemeyer C, Lampe CS, Clemens MR et al (1997) A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs 8:396–399
Kim MK, Lee KH, Hyun MS et al (2005) A multi-center, phase II clinical trial of padexol (paclitaxel) and cisplatin for patients suffering with advanced gastric cancer. Cancer Res Treat 37:349–353
Lee JJ, Kim SY, Chung HC et al (2009) A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer. Cancer Chemother Pharmacol 63:1083–1090
Narahara H, Fujitani K, Takiuchi H et al (2008) Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology 74:37–41
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10
Wils J (1996) The treatment of advanced gastric cancer. Semin Oncol 23:397–406
Mochiki E, Ohno T, Kamiyama Y et al (2006) Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer 95:1642–1647
Kawabata R, Fujiwara Y, Doki Y et al (2007) Phase I/II study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer. Oncology 72:219–225
Inada S, Tomidokoro T, Fukunari H et al (2009) Phase I/II trial of combination therapy with S-1 and weekly pacitaxel in patients with unresectable or recurrent gastric cancer. Cancer Chemother Pharmacol 63:267–273
Aajni JA, Lee FC, Singh DA et al (2006) Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24:663–667
Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221
Park SR, Kim HK, Kim CG et al (2008) Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma. Br J Cancer 98:1305–1311
Van Cutsem E, Moiseyenko VM, Tjulandin S, V325 Study Group et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997
Ilson DH (2007) Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol 25:3188–3190
Acknowledgments
This study was supported by a Grant of the Korean Health 21 R and D project, Ministry of Health and Welfare, Republic of Korea (0412-CR01-0704-0001).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, J.Y., Do, Y.R., Park, K.U. et al. Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer. Cancer Chemother Pharmacol 67, 527–532 (2011). https://doi.org/10.1007/s00280-010-1353-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-010-1353-6